Trametinib
About
Therapy type: Targeted therapy
Therapy strategy: MEK inhibition
Mappings
NCI Thesaurus: Trametinib (ncit:C77908)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (4) FDA (4) HSE (2) | BRAF p.V600E | Melanoma | Dabrafenib, Trametinib | |
| EMA (4) FDA (4) HSE (2) | BRAF p.V600K | Melanoma | Dabrafenib, Trametinib | |
| EMA (2) FDA (2) | BRAF p.V600E | Non-Small Cell Lung Cancer | Dabrafenib, Trametinib | |
| FDA (2) | BRAF p.V600E | Anaplastic Thyroid Cancer | Dabrafenib, Trametinib | |
| FDA (2) | BRAF p.V600E | Any solid tumor | Dabrafenib, Trametinib | |
| EMA (1) FDA (2) | BRAF p.V600E | Low-Grade Glioma, NOS | Dabrafenib, Trametinib | |
| EMA (1) FDA (1) | BRAF p.V600E | Melanoma | Trametinib | |
| EMA (1) FDA (1) | BRAF p.V600K | Melanoma | Trametinib | |
| EMA (2) | BRAF p.V600K | Non-Small Cell Lung Cancer | Dabrafenib, Trametinib | |
| EMA (1) | BRAF p.V600E | High-Grade Glioma, NOS | Dabrafenib, Trametinib |